Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Richard Dillon, Paolo Gallipoli et al.|Blood|2023Cited by 65
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Richard Dillon, Michael J. Austin et al.|Blood Neoplasia|2024Cited by 36
Venetoclax–based low intensity therapy in molecular failure of <i>NPM1</i>-mutated AMLCarlos Jiménez‐Chillón, Richard Dillon, Steven Knapper et al.|Blood Advances|2023Cited by 29
Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortiumCristina Astrid Tentori, David A. Sallman, Elena Riva et al.|HemaSphere|2024Cited by 11